These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study. Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025 [TBL] [Abstract][Full Text] [Related]
44. Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion-positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans. Zhou KI; Vashistha V; Guo A; Ahmed S; Kelley MJ JCO Precis Oncol; 2023 Mar; 7():e2200692. PubMed ID: 36926986 [TBL] [Abstract][Full Text] [Related]
46. The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. Shulman DS; DuBois SG Paediatr Drugs; 2020 Apr; 22(2):189-197. PubMed ID: 31965543 [TBL] [Abstract][Full Text] [Related]
47. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors. Naito Y; Mishima S; Akagi K; Hayashi N; Hirasawa A; Hishiki T; Igarashi A; Ikeda M; Kadowaki S; Kajiyama H; Kato M; Kenmotsu H; Kodera Y; Komine K; Koyama T; Maeda O; Miyachi M; Nishihara H; Nishiyama H; Ohga S; Okamoto W; Oki E; Ono S; Sanada M; Sekine I; Takano T; Tao K; Terashima K; Tsuchihara K; Yatabe Y; Yoshino T; Baba E Int J Clin Oncol; 2023 Jul; 28(7):827-840. PubMed ID: 37212982 [TBL] [Abstract][Full Text] [Related]
49. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients. Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351 [TBL] [Abstract][Full Text] [Related]
50. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. Kummar S; Berlin J; Mascarenhas L; van Tilburg CM; Geoerger B; Lassen UN; Schilder RJ; Turpin B; Nanda S; Keating K; Childs BH; Chirila C; Laetsch TW; Hyman DM; Drilon A; Hong DS Curr Probl Cancer; 2021 Dec; 45(6):100734. PubMed ID: 33865615 [TBL] [Abstract][Full Text] [Related]
51. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Boilève A; Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D Expert Opin Investig Drugs; 2021 Apr; 30(4):401-409. PubMed ID: 33641556 [No Abstract] [Full Text] [Related]
52. The Safety Profiles of Two First-Generation NTRK Inhibitors: Analysis of Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS) Database. Liguori V; Gaio M; Zinzi A; Cagnotta C; Riccardi C; Docimo G; Capuano A Biomedicines; 2023 Sep; 11(9):. PubMed ID: 37760979 [TBL] [Abstract][Full Text] [Related]
54. Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies. Orbach D; Sparber-Sauer M; Laetsch TW; Minard-Colin V; Bielack SS; Casanova M; Corradini N; Koscielniak E; Scheer M; Hettmer S; Bisogno G; Hawkins DS; Ferrari A Eur J Cancer; 2020 Sep; 137():183-192. PubMed ID: 32784118 [TBL] [Abstract][Full Text] [Related]
55. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review. El-Nassan HB; Al-Qadhi MA Eur J Med Chem; 2023 Oct; 258():115618. PubMed ID: 37413881 [TBL] [Abstract][Full Text] [Related]
56. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China. Xu C; Si L; Wang W; Li Z; Song Z; Wang Q; Liu A; Yu J; Fang W; Zhong W; Wang Z; Zhang Y; Liu J; Zhang S; Cai X; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Pu X; Lin R; Liu W; Rao C; Lv D; Yu Z; Lei L; Li X; Tang C; Zhou C; Zhang J; Xue J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Hu X; Zhou J; Zhu Z; Li Y; Qiu H; Xia F; Lu Y; Chen X; Ge R; Dai E; Han Y; Pan W; Luo J; Jia H; Dong X; Pang F; Wang K; Wang L; Zhu Y; Xie Y; Lin X; Cai J; Wei J; Lan F; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Wan B; Lv D; Wei Q; Kang J; Zhang J; Zhang C; Yu G; Ou J; Shi L; Li Z; Liu Z; Liu J; Yang N; Wu L; Wang H; Jin G; Yang L; Wang G; Fang M; Fang Y; Li Y; Wang X; Zhang Y; Ma S; Wang B; Zhang X; Song Y; Lu Y Thorac Cancer; 2022 Nov; 13(21):3084-3097. PubMed ID: 36127731 [TBL] [Abstract][Full Text] [Related]
57. Target-Driven Tissue-Agnostic Drug Approvals-A New Path of Drug Development. Thein KZ; Myat YM; Park BS; Panigrahi K; Kummar S Cancers (Basel); 2024 Jul; 16(14):. PubMed ID: 39061168 [TBL] [Abstract][Full Text] [Related]
58. TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs. Han SY Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34209967 [TBL] [Abstract][Full Text] [Related]
59. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. Naito Y; Mishima S; Akagi K; Igarashi A; Ikeda M; Okano S; Kato S; Takano T; Tsuchihara K; Terashima K; Nishihara H; Nishiyama H; Hiyama E; Hirasawa A; Hosoi H; Maeda O; Yatabe Y; Okamoto W; Ono S; Kajiyama H; Nagashima F; Hatanaka Y; Miyachi M; Kodera Y; Yoshino T; Taniguchi H Int J Clin Oncol; 2020 Mar; 25(3):403-417. PubMed ID: 31974683 [TBL] [Abstract][Full Text] [Related]
60. Evolving role of entrectinib in treatment of Chawla N; Bui NQ; Seetharam M Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]